	US 12,138,254 B2
	Chronic nightly dosing of lasmiditan for migraine prevention
Robert Russell Conley, Annapolis, MD (US); Gudarz Davar, Indianapolis, IN (US); and Kirk Willis Johnson, Carmel, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Appl. No. 17/271,950
Filed by Eli Lilly and Company, Indianapolis, IN (US)
PCT Filed Sep. 3, 2019, PCT No. PCT/US2019/049340 § 371(c)(1), (2) Date Feb. 26, 2021, PCT Pub. No. WO2020/051137, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/726,585, filed on Sep. 4, 2018.
Prior Publication US 2021/0338655 A1, Nov. 4, 2021
Int. Cl. A61K 31/4545 (2006.01); A61K 9/00 (2006.01); A61P 25/06 (2006.01)

CPC A61K 31/4545 (2013.01) [A61K 9/0053 (2013.01); A61P 25/06 (2018.01)]

10 Claims

1. A method for the prevention of migraine, in a patient in need thereof, comprising nightly administering to said patient 25-200 mg per oral dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, at bedtime, for at least five consecutive nights.